BG Medicine Prices Public Offering, Reaches Stock Purchase Agreement | GenomeWeb

NEW YORK (GenomeWeb News) – BG Medicine today announced a public offering of its stock that it expects to bring in $11.1 million in net proceeds.

The cardiovascular diagnostics firm also announced a common stock purchase agreement for up to $12 million, as well as preliminary financials for the fourth quarter and full-year ended Dec. 31, 2012.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: mutations linked to nasopharyngeal carcinoma, salivary proteins common among oral squamous cell carcinoma patients, and more.

At Wired, a science journalist discusses her decision not to undergo BRCA testing.

The Japan Times says regulations are needed to oversee human genome-editing research.

In PLOS this week: molecular surveillance of S. Typhi, genome-wide association study of attention in children, and more.